Population-Based Comparison of Different Risk Stratification Systems Among Prostate Cancer Patients.
comparison
population-based
prostate cancer
prostate cancer-specific mortality
risk stratification system
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
12
2020
accepted:
16
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
It is not known which risk stratification system has the best discrimination ability for predicting prostate cancer death. We identified patients with non-metastatic primary prostate adenocarcinoma diagnosis between 2004 and 2015 using the Surveillance, Epidemiology, and End Results database. Patients were categorized in different risk groups using the three frequently used risk stratification systems of the National Comprehensive Cancer Network guideline (NCCN-g), American Urological Association guideline (AUA-g), and European Association of Urology guideline (EAU-g), respectively. Associations between risk classification and prostate cancer-specific mortality (PCSM) were determined using Kaplan-Meier analyses and multivariable regression with Cox proportional hazards model. Area under the receiver operating characteristics curve (AUC) analyses were used to test the discrimination ability of the three risk grouping systems. We analyzed 310,062 patients with a median follow-up of 61 months. A total of 36,368 deaths occurred, including 6,033 prostate cancer deaths. For all the three risk stratification systems, the risk groups were significantly associated with PCSM. The AUC of the model relying on NCCN-g, AUA-g, and EAU-g risk stratification systems for PCSM at specifically 8 years were 0.818, 0.793, and 0.689 in the entire population; 0.819, 0.795, and 0.691 in Whites; 0.802, 0.777, and 0.681 in Blacks; 0.862, 0.818, and 0.714 in Asians; 0.845, 0.806, and 0.728 in Chinese patients. Regardless of the age, marital status, socioeconomic status, and treatment modality, AUC of the model relying on NCCN-g and AUA-g for PCSM was greater than that relying on EAU-g; AUC of the model relying on NCCN-g system was greater than that of the AUA-g system. The NCCN-g and AUA-g risk stratification systems perform better in discriminating PCSM compared to the EAU-g system. The discrimination ability of the NCCN-g system was better than that of the AUA-g system. It is recommended to use NCCN-g to evaluate risk groups for prostate cancer patients and then provide more appropriate corresponding treatment recommendations.
Sections du résumé
BACKGROUND
BACKGROUND
It is not known which risk stratification system has the best discrimination ability for predicting prostate cancer death.
METHODS
METHODS
We identified patients with non-metastatic primary prostate adenocarcinoma diagnosis between 2004 and 2015 using the Surveillance, Epidemiology, and End Results database. Patients were categorized in different risk groups using the three frequently used risk stratification systems of the National Comprehensive Cancer Network guideline (NCCN-g), American Urological Association guideline (AUA-g), and European Association of Urology guideline (EAU-g), respectively. Associations between risk classification and prostate cancer-specific mortality (PCSM) were determined using Kaplan-Meier analyses and multivariable regression with Cox proportional hazards model. Area under the receiver operating characteristics curve (AUC) analyses were used to test the discrimination ability of the three risk grouping systems.
RESULTS
RESULTS
We analyzed 310,062 patients with a median follow-up of 61 months. A total of 36,368 deaths occurred, including 6,033 prostate cancer deaths. For all the three risk stratification systems, the risk groups were significantly associated with PCSM. The AUC of the model relying on NCCN-g, AUA-g, and EAU-g risk stratification systems for PCSM at specifically 8 years were 0.818, 0.793, and 0.689 in the entire population; 0.819, 0.795, and 0.691 in Whites; 0.802, 0.777, and 0.681 in Blacks; 0.862, 0.818, and 0.714 in Asians; 0.845, 0.806, and 0.728 in Chinese patients. Regardless of the age, marital status, socioeconomic status, and treatment modality, AUC of the model relying on NCCN-g and AUA-g for PCSM was greater than that relying on EAU-g; AUC of the model relying on NCCN-g system was greater than that of the AUA-g system.
CONCLUSIONS
CONCLUSIONS
The NCCN-g and AUA-g risk stratification systems perform better in discriminating PCSM compared to the EAU-g system. The discrimination ability of the NCCN-g system was better than that of the AUA-g system. It is recommended to use NCCN-g to evaluate risk groups for prostate cancer patients and then provide more appropriate corresponding treatment recommendations.
Identifiants
pubmed: 33928035
doi: 10.3389/fonc.2021.646073
pmc: PMC8076565
doi:
Types de publication
Journal Article
Langues
eng
Pagination
646073Informations de copyright
Copyright © 2021 Xie, Gao, Ma, Gu, Li, Lyu, Bai, Chen, Ren and Liu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur Urol. 2015 Feb;67(2):326-33
pubmed: 24998118
J Clin Endocrinol Metab. 1991 Jun;72(6):1242-8
pubmed: 1827450
J Natl Cancer Inst. 2009 Jun 16;101(12):878-87
pubmed: 19509351
Cancer Causes Control. 2014 Jan;25(1):81-92
pubmed: 24178398
J Urol. 2018 Mar;199(3):683-690
pubmed: 29203269
Eur Urol. 2020 Feb;77(2):180-188
pubmed: 31606332
BJU Int. 2017 Nov;120(5B):E87-E95
pubmed: 28464446
Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):828-35
pubmed: 26530751
Lancet. 1992 Apr 11;339(8798):887-9
pubmed: 1348296
Cancer Causes Control. 2001 Oct;12(8):703-11
pubmed: 11562110
Biometrics. 2000 Jun;56(2):337-44
pubmed: 10877287
PLoS Med. 2016 Aug 02;13(8):e1002063
pubmed: 27483464
J Clin Oncol. 2009 Sep 10;27(26):4300-5
pubmed: 19636023
Eur Urol. 2015 Jan;67(1):157-164
pubmed: 24486307
BMC Med. 2018 Feb 28;16(1):31
pubmed: 29490658
J Natl Cancer Inst. 2000 Jan 5;92(1):61-8
pubmed: 10620635
JAMA Oncol. 2020 Dec 1;6(12):1912-1920
pubmed: 33090219
J Clin Oncol. 2018 Feb 20;36(6):581-590
pubmed: 29185869
J Urol. 2005 Jun;173(6):1938-42
pubmed: 15879786
Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):621-627
pubmed: 31271825
J Urol. 2019 Mar;201(3):486-495
pubmed: 30366021
Eur Urol Oncol. 2020 Jun;3(3):270-280
pubmed: 32303478
Nature. 2020 Apr;580(7801):93-99
pubmed: 32238934
Nutr Cancer. 1999;33(1):20-5
pubmed: 10227039
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
Res Rep Urol. 2019 Feb 27;11:29-42
pubmed: 30881943
Cancer. 2015 May 1;121(9):1414-21
pubmed: 25492369